Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

a and information to the FDA. We have since provided some supporting data to the FDA, and are in the process of finalizing a complete response to be submitted as soon as practicable."

Linda L. Chang, Senior Vice President and Chief Financial Officer, commented, "In 2012 we set an aggressive goal of reducing our monthly cash usage to further optimize our government contracting biodefense business model. We successfully met this goal while securing additional funding of $7.5 million through a credit facility provided by GE Capital.  These achievements, along with our ongoing efforts, will continue to ensure we have the flexibility to capably manage our expenses and capital requirements in 2013."

Year-End 2012 Financial ResultsRevenueFor the year ended December 31, 2012, PharmAthene recognized revenue of $25.2 million, compared to $24.3 million in 2011. Revenue in 2012 was derived primarily from development contracts with the U.S. government for the Company's biodefense product candidates.

Revenue for the SparVax® program increased in 2012 to approximately $22.9 million, compared to $19.3 million in 2011. Revenue in 2012 was primarily attributable to the achievement of several contract milestones, including the completion of Final Drug Product manufacture, progress in the development of bioanalytical and analytical assays, and the execution of non-clinical studies.

Revenue for the rBChE bioscavenger program in 2012 was approximately $1.8 million, compared to $0.7 million in 2011, corresponding with significant technical progress achieved during the year. On July 31, 2012 the Department of Defense exercised a $2.5 million option to continue to fund the rBChE program under its 2011 fixed price contract.

Revenue for the Valortim® program in 2012 was $0.5 million, compared to $3.7 million in 2011 as a result of the completion of the 2007 NIAID contract for Valortim® in the first quart
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Pinnacle Biologics, a,private, full-service pharmaceutical and biotech ... agreement with pharmexx to expand sales,support activities in ... of the,agreement were not disclosed., Viren Grover, ... to conclude this agreement with pharmexx, which allows ...
... ON, July 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and six months ended May 31, 2008. All dollar ... At May 31, 2008, our cash and cash ... 29, 2008., The net loss for the second ...
... Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ABBOTT PARK, ... V(TM) USA post-approval study, with six,hospital centers already recruiting and enrolling ... the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The XIENCE V USA ...
Cached Biology Technology:Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2Vasogen Announces Second Quarter 2008 Results 2Vasogen Announces Second Quarter 2008 Results 3Vasogen Announces Second Quarter 2008 Results 4Vasogen Announces Second Quarter 2008 Results 5Vasogen Announces Second Quarter 2008 Results 6Vasogen Announces Second Quarter 2008 Results 7Vasogen Announces Second Quarter 2008 Results 8Vasogen Announces Second Quarter 2008 Results 9Vasogen Announces Second Quarter 2008 Results 10Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/29/2014)... academics in the University of Bristol,s Nutrition and Behaviour ... calories into account when planning meals. , The research, ... of Ingestive Behavior Conference (SSIB 2014) in Seattle, USA ... we do. , The team was led by Professor ... Experimental Psychology. , As part of a Biotechnology and ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... BETHESDA, MD August 23, 2007 On August 16, the ... blood-thinner warfarin, sold under the brand name Coumadin. The new ... that may be safer for patients with variations in two ... through genetic testing, which may be a useful tool in ...
... Optics 2007 (FiO), the 91st Annual Meeting of the ... 16-20 in San Jose, Calif., alongside Laser Science XXIII, ... of Laser Science. Reporters interested in obtaining a ... at 202.416.1437, cmorri@osa.org . FiO RESEARCH ...
... system designed for brain tumor therapy has shown promising ... devised by University of Nottingham scientists. The project, conducted ... Human Development, will be featured in the September issue ... cancers is particularly difficult for a number of reasons, ...
Cached Biology News:American College of Medical Genetics responds to new FDA labeling decision for warfarin 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: